Jan 9 (Reuters) - The U.S. Environmental Protection Agency will reassess the safety of herbicide paraquat, its administrator Lee Zeldin said on Friday on X, adding that the body is requiring manufacturers to thoroughly prove that current uses are safe in real-world conditions.
Syngenta, which markets paraquat under the brand name Gramoxone, is among the herbicide's major sellers.
The Swiss-based agricultural chemical company is facing several lawsuits in the U.S., where plaintiffs allege exposure to paraquat caused them to develop Parkinson's, a degenerative brain disease that leads to loss of muscle coordination.
It has previously said there was "no credible evidence" that paraquat causes Parkinson's.
In agricultural settings, paraquat is mostly applied to soybean, corn and cotton crop fields to control invasive weeds and grasses, according to the Environmental Protection Agency.
(Reporting by Costas Pitas and Pooja Menon; Editing by Alan Barona)
latest_posts
- 1
Merz visit highlights new strategic, and strained, Germany-Israel bond - 2Reconnecting with an old friend is a story of distance, loss and rediscovery
- 3Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- 4The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- 574 suicide warnings and 243 mentions of hanging: What ChatGPT said to a suicidal teen
- IDF destroys Hezbollah rocket launcher used in large rocket salvo towards Haifa, Galilee
- New heart disease calculator predicts 30-year risk for young adults
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
- Roman around the Christmas tree | Space photo of the day for Dec. 25, 2025
- 10 Delectable Specialty Mixed drinks
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- Malaysia To Revive Search for Missing Flight MH370
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
